These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 10348681)

  • 1. Control of HIV despite the discontinuation of antiretroviral therapy.
    Lisziewicz J; Rosenberg E; Lieberman J; Jessen H; Lopalco L; Siliciano R; Walker B; Lori F
    N Engl J Med; 1999 May; 340(21):1683-4. PubMed ID: 10348681
    [No Abstract]   [Full Text] [Related]  

  • 2. Dynamics of the pool of infected resting CD4 HLA-DR- T lymphocytes in patients who started a triple class five-drug antiretroviral regimen during primary HIV-1 infection.
    Sankatsing SU; van Praag RM; van Rij RP; Rientsma R; Jurriaans S; Lange JM; Prins JM; Schuitemaker H
    Antivir Ther; 2003 Apr; 8(2):137-42. PubMed ID: 12741626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of antiretroviral therapy on plasma HIV RNA.
    Saag MS
    J Biol Regul Homeost Agents; 1995; 9(3):105-6. PubMed ID: 8782017
    [No Abstract]   [Full Text] [Related]  

  • 4. Immune control of HIV-1 after early treatment of acute infection.
    Rosenberg ES; Altfeld M; Poon SH; Phillips MN; Wilkes BM; Eldridge RL; Robbins GK; D'Aquila RT; Goulder PJ; Walker BD
    Nature; 2000 Sep; 407(6803):523-6. PubMed ID: 11029005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia.
    Zaunders JJ; Cunningham PH; Kelleher AD; Kaufmann GR; Jaramillo AB; Wright R; Smith D; Grey P; Vizzard J; Carr A; Cooper DA
    J Infect Dis; 1999 Aug; 180(2):320-9. PubMed ID: 10395845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interruption of antiretroviral therapy to augment immune control of chronic HIV-1 infection: risk without reward.
    Abbas UL; Mellors JW
    Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13377-8. PubMed ID: 12370421
    [No Abstract]   [Full Text] [Related]  

  • 7. [Viral dynamics in the course of HIV-1 infection: pathogenetic features and new therapeutic prospects].
    Marcello A; Giacca M
    Pathologica; 2000 Aug; 92(4):291-3. PubMed ID: 11029891
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4+ T cell decline in human immunodeficiency virus-infected patients: implications for intermittent therapeutic strategies.
    Tebas P; Henry K; Mondy K; Deeks S; Valdez H; Cohen C; Powderly WG
    J Infect Dis; 2002 Sep; 186(6):851-4. PubMed ID: 12198623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV therapeutics: points from the recent literature.
    Laurence J
    AIDS Read; 2003 Jul; 13(7):305, 307. PubMed ID: 12889448
    [No Abstract]   [Full Text] [Related]  

  • 10. [New biological monitoring of HIV infection].
    Morand-Joubert L
    Rev Prat; 1998 Mar; 48(5):472-7. PubMed ID: 9781107
    [No Abstract]   [Full Text] [Related]  

  • 11. CD8 T-cell response to antiretroviral therapy.
    Stricker RB; Goldberg B
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Jun; 15(2):176-7. PubMed ID: 9241121
    [No Abstract]   [Full Text] [Related]  

  • 12. Ongoing HIV dissemination during HAART.
    Grossman Z; Polis M; Feinberg MB; Grossman Z; Levi I; Jankelevich S; Yarchoan R; Boon J; de Wolf F; Lange JM; Goudsmit J; Dimitrov DS; Paul WE
    Nat Med; 1999 Oct; 5(10):1099-104. PubMed ID: 10502799
    [No Abstract]   [Full Text] [Related]  

  • 13. Down-regulation of interleukin-7 receptor (CD127) in HIV infection is associated with T cell activation and is a main factor influencing restoration of CD4(+) cells after antiretroviral therapy.
    Benito JM; López M; Lozano S; González-Lahoz J; Soriano V
    J Infect Dis; 2008 Nov; 198(10):1466-73. PubMed ID: 18847371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV preferentially infects HIV-specific CD4+ T cells.
    Douek DC; Brenchley JM; Betts MR; Ambrozak DR; Hill BJ; Okamoto Y; Casazza JP; Kuruppu J; Kunstman K; Wolinsky S; Grossman Z; Dybul M; Oxenius A; Price DA; Connors M; Koup RA
    Nature; 2002 May; 417(6884):95-8. PubMed ID: 11986671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 and HAART: a time to cure, a time to kill.
    Saag MS; Kilby JM
    Nat Med; 1999 Jun; 5(6):609-11. PubMed ID: 10371490
    [No Abstract]   [Full Text] [Related]  

  • 16. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.
    Deeks SG; Wrin T; Liegler T; Hoh R; Hayden M; Barbour JD; Hellmann NS; Petropoulos CJ; McCune JM; Hellerstein MK; Grant RM
    N Engl J Med; 2001 Feb; 344(7):472-80. PubMed ID: 11172188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Highly active antiretroviral therapy leads to a significant but delayed increase of CD45RA+ T-helper cells.
    Degen O; Stellbrink HJ; Lauer J; van Lunzen J
    AIDS; 1998 Sep; 12(13):1715-6. PubMed ID: 9764793
    [No Abstract]   [Full Text] [Related]  

  • 18. HIV RNA viral load and CD4+ T-cell counts in HIV-infected pregnant women with and without treatment discontinuation in early pregnancy.
    Tamburrini E; Ravizza M; Floridia M; Tibaldi C; Alberico S; Anzidei G; Maccabruni A; Meloni A; Antoni AD; Mori F; Dalzero S; Conservan V; Pinnetti C; Ferrazzi E;
    Antivir Ther; 2008; 13(4):519-27. PubMed ID: 18672530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
    Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
    J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
    Li H; Zheng YH; Shen Z; Liu M; Liu C; He Y; Chen J; Ou QY; Huang ZL
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(42):2973-6. PubMed ID: 18261327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.